Advertisement

Drugs

, Volume 75, Issue 10, pp 1161–1164 | Cite as

Trelagliptin: First Global Approval

  • Kate McKeageEmail author
AdisInsight Report

Abstract

Trelagliptin (Zafatek®) is an orally active dipeptidyl peptidase (DPP)-4 inhibitor developed by Takeda and approved in Japan for the treatment of type 2 diabetes mellitus (T2DM). Unlike other approved agents of its class, which are usually administered once daily, trelagliptin can be administered once weekly. Phase II development of trelagliptin was discontinued in the USA and EU, as Takeda considered that the costs associated with obtaining approval in these markets were prohibitive. This article summarizes the milestones in the development of trelagliptin leading to this first approval for T2DM.

Keywords

Metformin Glycaemic Control Sitagliptin Linagliptin Alogliptin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Disclosure

The preparation of this review was not supported by any external funding. During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. K. McKeage is a salaried employee of Adis, Springer SBM.

References

  1. 1.
    Takeda. Zafatek (trelagliptin): Japanese prescribing information. 2015. http://www.takedamed.com/content/medicine/pdf/zafatek.pdf. Accessed 27 May 2015.
  2. 2.
    Inzucchi SE, Bergenstal R, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015;58:429–42.PubMedCrossRefGoogle Scholar
  3. 3.
    Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27:1218–24.PubMedCrossRefGoogle Scholar
  4. 4.
    Kruk ME, Schwalbe N. The relation between intermittent dosing and adherence: preliminary insights. Clin Ther. 2006;28:1989–95.PubMedCrossRefGoogle Scholar
  5. 5.
    PPD Inc. Takeda aquires the rights to DPP4 inhibitors granted to PPD [media release]. 13 July 2005. www.ppdi.com.
  6. 6.
    Actavis Inc. Actavis completes acquisition of Furiex Pharmaceuticals [media release]. 2 July 2014. www.actavis.com.
  7. 7.
    Drucker DJ. The role of gut hormones in glucose homeostasis. J Clin Invest. 2007;117:24–32.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Inagaki N, Onouchi H, Sano H, et al. SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2:125–32.PubMedCrossRefGoogle Scholar
  9. 9.
    Inagaki N, Onouchi H, Maezawa H, et al. Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study. Lancet Diabetes Endocrinol. 2015;3:191–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations